[1] Lleo A, Marzorati S, Anaya JM, et al. Primary biliary cholangitis: a comprehensive overview. Hepatobil Int,2017,11: 485-499.
[2] Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol,2015,48:192-197.
[3] Yoo WS, Chung HK. Recent advances in autoimmune thyroid diseases. Endocrinol Metab(Seoul),2016,31:379-385.
[4] Crowe JP, Christensen E, Butler J, et al. Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology,1980,78: 1437-1441.
[5] Elta GH, Seperski RA, Goldberg MJ, et al. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dis Sci,1983, 28:971-975.
[6] Gershwin ME, Selmi C, Worman HJ, et al.Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology,2005,42:1194-1202.
[7] Floreani A, Mangini C, Reig A, et al. Thyroid dysfunction in primary biliary cholangitis: a comparative study at two european centers. Am J Gastroenterol, 2017,112:114-119.
[8] Biró E, Szekanecz Z, Czirják L, et al. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol,2006,25:240-245.
[9] Ku? A,Ar?ukowicz-Grabowska M, Szymański K,et al.Genetic risk factors for autoimmune thyroid disease might affect the susceptibility to and modulate the progression of primary biliary cholangitis.J Gastrointestin Liver Dis,2017,26:245-252.
[10] Milkiewicz P, Pache I, Buwaneswaran H, et al. The PTPN22 1858T variant is not associated with primary biliary cirrhosis. Tissue Antigens,2006,67:434-437.
[11] de Boer YS, van Gerven NM, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology,2014,147:443-452.
[12] Raszeja-Wyszomirska J, Miazgowski T. Osteoporosis in primary biliary cirrhosis of the liver. Prz Gastroenterol,2014,9:82-87.
[13] Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev,2014,13:391-397.
[14] Nystr?m HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol (Oxf),2013,78:768-776.
[15] Bano A, Chaker L, Plompen EP,et al.Thyroid function and the risk of nonalcoholic fatty liver disease: the rotterdam study.J Clin Endocrinol Metab, 2016,101:3204-3211.
[16] Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholan-gitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology,2019,69:394-419.
[17] Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology,2015,148:751-761.
[18] Kuiper EM, Hansen BE, de Vries RA, et al. Improved prog-nosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology,2009,136:1281-1287.
[19] Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid,2014,24:1670-1751.
[20] Muratori P, Fabbri A, Lalanne C, et al. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol,2015,27:1175-1179.
[21] Rigam onti C, Shand LM, Feudjo M, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut,2006,55:388-394.
[22] Wang L, Zhang FC, Chen H, et al. Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study. World J Gastroenterol,2013,19:5131-5137. |
